Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341

Cancer Investigation

Volumn 29, Issue 4, 2011, Pages 247-252

  Fang, Yong ^a   Hu, Yi ^a,b   Wu, Peng ^a   Wang, Beibei ^a   Tian, Yuan ^a   Xia, Xi ^a   Zhang, Qinghua ^a   Chen, Tong ^a   Jiang, Xuefeng ^a   Ma, Quanfu ^a   Xu, Gang ^a   Wang, Shixuan ^a   Zhou, Jianfeng ^a   Ma, Ding ^a   Meng, Li ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Histone deacetylase inhibitor; Ovarian cancer; p21; Proteasome inhibitor

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; CYTOCHROME C; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL SURVIVAL; CYTOSOLIC FRACTION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INCUBATION TIME; MITOCHONDRION; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA ISOLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOCHROMES C; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; OVARIAN NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA INTERFERENCE; TIME FACTORS;

EID: 79953802546     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.496756     Document Type: Article

References (31)

1. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9(6):415-428.
2. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-784. (Pubitemid 44348499)
3. Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007;7(4):583-598. (Pubitemid 46690964)
4. Carey N, LaThangue NB. Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol 2006, 6(4):369-375. (Pubitemid 44040838)
5. Duvic M, Vu J. A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphom. Expert Opin Investig Drugs 2007;16:1111-1120. (Pubitemid 47074165)
6. Zhu K, Qu D, Sakamoto T, Fukasawa I, Hayashi M, Inaba N. Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors. Arch Gynecol Obstet 2008;277(1):15-19. (Pubitemid 350160080)
7. Adams J.The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4(5):349-360. (Pubitemid 38579481)
8. Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003;4: 192-201. (Pubitemid 36288041)
9. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003;29(Suppl. 1):3-9. (Pubitemid 36626287)
10. Ling YH, Liebes L, Jiang J.D, Holland J.F, Elliott P.J, Adams J, Muggia F.M, Perez-Soler R. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003;9(3):1145-1154. (Pubitemid 36323724)
11. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, JosephM, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101(6):2377-2380. (Pubitemid 36302084)
12. Russo A, Fratto ME, Bazan V, Schiro V, Agnese V, Cicero G, Vincenzi B, Tonini G, Santini D. Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. Expert OpinTher Targets 2007;11(12):1571-1586. (Pubitemid 350300962)
13. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004;10(11):3839-3852. (Pubitemid 38697620)
14. Denlinger CE, Keller MD,MayoMW,Broad RM, JonesDR. Combined proteasome and histone deacetylase inhibitor in non-small cell lung cancer. J Thorac Cardiovasc Surg 2004;127:1078-1986.
15. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.Mol CancerTher 2007;6(1):37-50. (Pubitemid 46206667)
16. Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S, Ma D. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 2008;271(2): 260-271.
17. Livak KJ, Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001;25:402-408. (Pubitemid 34164012)
18. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009;280(2): 192-200.
19. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009;280(2):125-133.
20. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih Ie M, Roden RB. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006;66(7):3754-3763.
21. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2006;6:3719-3728.
22. Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P, Cognetti F, Humphreys R, Peschle C, Testa U. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 2007;12(4):635-655. (Pubitemid 46411475)
23. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2000;10:3839-3852. (Pubitemid 38697620)
24. Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008;112(7):2917-2926.
25. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, Johnstone RW. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003;63(15):4460-4471. (Pubitemid 36951018)
26. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400-414.
27. Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995;375(6527):159-161.
28. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002;1(11):937-941.
29. Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002;179(1):1-14. (Pubitemid 34195647)
30. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000;1471:M43-M56.
31. Gartel AL. The conflicting roles of the cdk inhibitor p21CIP1/WAF1 in apoptosis. Leuk Res 2005;29:1237-1238. (Pubitemid 41297632)